News archive 2005
1 October 2005
INPHARMATICA Licenses ADMENSA INTERACTIVE to Mochida of Japan
1 October 2005
AGENDIA BV Closes 2nd Financing Round
1 October 2005
INPHARMATICA Licenses Biopendium to Schering and Announces Druggability Collaboration
1 October 2005
BG MEDICINE and FDA to Conduct Joint Biomarker Discovery Study
1 October 2005
ABLYNX Successful in Maintaining Key Claims after NANOBODY™ Patent Challenge
1 October 2005
CROPDESIGN - Multimillion EURO Deal on Developing Higher Yielding Crops
1 July 2005
NEURO3D - New Board Appointments
1 July 2005
AGENDIA Acquires ISO Accreditation for MammaPrint(R) Breast Cancer Risk Assessment Test
1 July 2005
ABLYNX Successful in Maintaining Key Claims after NANOBODY™ Patent Challenge
1 July 2005
ABLYNX/GILDE - Dr. Hennie Hoogenboom Appointed as Chief Scientific Officer
1 July 2005
IDEA AG - Celtic Pharma Acquires Stake in IDEA AG
1 July 2005
INPHARMATICA Announces CHEMATICA™ Collaboration with TIBOTEC PHARMACEUTICALS
1 July 2005
BG MEDICINE Announces Agreement with Boehringer Ingelheim Pharmaceuticals
1 July 2005
GILDE Sells Equity Stake in Swiss Biotech Company to Roche
1 July 2005
INPHARMATICA Launches ANNOTATION EXPRESS™
1 April 2005
PIERIS PROTEOLAB AG and Syngenta Biopharma Collaborate to Develop ANTICALINS®
1 April 2005
INPHARMATICA Launches STARLITE™ and DRUGSTORE™
1 April 2005
IDEA AG Starts Phase III Study with IDEA-033
1 April 2005
INPHARMATICA Launches GPCR SARfari™: New Knowledge Base Provides Essential Information
1 April 2005
NEURO3D Reports Positive Results from Phase II Trials of Ocaperidone in Schizophrenia
1 April 2005
BG MEDICINE to Present at the SG Cowen 25th Annual Health Care Conference
1 January 2005
GLYCART Biotechnology appoints Andreas Emmenegger as Chief Financial Officer
1 January 2005
BEYOND GENOMICS Becomes BG MEDICINE, Appoints New President, Sharpens Focus
1 January 2005
NEURO3D Named by Tornado Insider Among Europe's Top 100 Private Tech Companies
1 January 2005
INPHARMATICA Announces PHARMACARTA™ Partnership with Pfizer
1 January 2005
INPHARMATICA Announces Appointment of John Lisle as Chief Executive Officer
1 January 2005
GILDE Leads €31.5 Million Financing Round of NEURO3D

